Cytisinicline is an emerging smoking cessation therapy that has demonstrated strong quit rates and favorable tolerability in clinical trials, positioning it as a promising new option for individuals looking to overcome nicotine dependence.
What began as a mission-driven alternative to traditional PBMs has grown into a trusted partner for organizations across the country. As ClearScript has evolved, so has our vision for the...
Rising stop loss premiums are putting new pressure on self funded employers and the brokers who advise them. Many plans are seeing increased renewal rates, driven in part by specialty...
ClearScript remains committed to transparency. For plan sponsors, recent federal reforms mean PBM decisions should be easier to understand and…
Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults…
As pharmacy costs continue to rise, employers and their broker partners are under increasing pressure to navigate complexity, manage uncertainty,…
Manufacturer Novo Nordisk received FDA approval for oral semiglutide on 12/22/2025. These new indications for Wegovy tablets are for chronic weight management and to reduce the risk of major cardiovascular events in adults with obesity or overweight.
Join us as we discuss ClearScript’s 2025 highlights such as new member lives, implementation success rates, client satisfaction, and innovative new PBM products that were launched and those that are in the pipeline.
At ClearScript, we are committed to keeping you informed and prepared for the evolving landscape of Pharmacy Benefit Management (PBM). This update highlights key regulatory changes, industry updates, and ClearScript’s proactive strategies.
If you’re managing pharmacy benefits in 2026, you’re likely facing rising costs, new therapies, and tough decisions. So how do you stay ahead? It starts with understanding what drives trend and how to manage it with confidence.
Centanafadine is a novel, first-in-class, non-stimulant under development for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. It’s rapid onset & good safety profile would likely result in uptake for patients who do not respond to generic stimulant / non-stimulant therapy options.
In this Coffee with ClearScript episode, Reese Puckett, VP of PBM Operations, explains how pricing benchmarks work, what cost-plus really means, and the actual solutions to controlling pharmacy spend.